

Emily Shaw

Senior Associate

+1 202 239 3768

emily.shaw@alston.com

Washington, D.C. | The Atlantic Building, 950 F Street, NW | Washington, DC 20004-1404

Emily offers sound and strategic counsel to clients on transactional, regulatory, and legislative issues.



Emily Shaw is a senior associate with Alston & Bird's Health Care Group. She advises a broad range of health care providers and life sciences businesses on emerging policy issues and complex regulatory matters. Emily focuses her practice on drug pricing and a broad range of health care coverage, coding, and payment matters. Her clients rely on her for legislative and regulatory policy analysis and advocacy. Emily has developed a niche practice on 340B Drug Pricing Program matters. She is recognized by *The Best Lawyers in America*® as "One to Watch" in Health Care Law.

Emily earned her J.D. from Cornell Law School. She holds a bachelor's of music from the University of Missouri–Kansas City, where she majored in oboe performance. Before joining Alston & Bird, Emily worked in the Kansas City office of a national firm, where she practiced in the health care group.

Representative Experience

- Providing strategic policy and regulatory counsel on a broad range of drug and device pricing and reimbursement matters, including the Medicaid Drug Rebate Program, Medicare Parts B and D, government procurement, and importation.
- Counseling hospitals and other covered entities on 340B Drug Pricing Program matters, including compliance, audit preparation and response, and policy developments.
- Advising health care clients on surprise billing, price transparency, COVID-19 response, and other emerging legislative and regulatory policy developments.
- Providing strategic counsel on advocacy efforts on emerging health care policy issues, including the development of comment letters and assistance with outreach to congressional and agency staff.
- Assisting life sciences and provider clients with development of innovative payment models.
- Providing legislative and regulatory counsel to several biopharmaceutical companies on matters such as biosimilar development, rare disease therapies, and patient assistance programs.
- Counseling on HIPAA, Part 2, GINA, GDPR, and other international, federal, and state privacy laws.
- Providing regulatory counsel for securities filings, mergers and acquisitions, and other transactional matters.

Publications & Presentations

Publications

- "The 340B Program Compliance Update," in *2019 Health Law and Compliance Update*, Wolters Kluwer, 2018.
- "Competitive Bid Program Reform Options and Opportunities," *HME News*, March 22, 2017.
- "Telemental Health: Key Compliance Considerations," *Compliance Today*, July 2016.

- “E-Health, Privacy, and Security Law,” in *E-Health Industry Overview*, 3rd ed., Bloomberg Law, 2016.

Professional & Community Engagement

- American Health Lawyers Association, Women’s Leadership Council
- Greater Kansas City Society of Healthcare Attorneys, president (2018–2019), secretary (2017–2018)
- Junior League of Washington
- Junior League of Kansas City (2017–2019)

Education

- Cornell University (J.D., 2015)
- University of Missouri – Kansas City (B.M., 2011)

Admitted to Practice

- District of Columbia
- Missouri

Related Services

Health Care | Health Care Legislative & Public Policy | Corporate Health Care Transactions | Fraud & Abuse | HIPAA/Health Information Privacy, Security & Breach Response | Privacy, Cyber & Data Strategy